Stellar Pharmaceuticals Inc.
TSX VENTURE : SLX
OTC Bulletin Board : SLXCF

Stellar Pharmaceuticals Inc.

March 28, 2007 07:30 ET

Stellar Pharmaceuticals Schedules Fourth Quarter and Year End Financial Results and Conference Call

LONDON, ONTARIO--(CCNMatthews - March 28, 2007) - Stellar Pharmaceuticals Inc., (TSX VENTURE:SLX)(OTCBB:SLXCF) ("Stellar"), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced that it plans to release its 2006 fourth quarter and year-end financial results prior to the opening of the stock market on Friday, March 30, 2007. Management will conduct a conference call that morning at 11:00 a.m. Eastern Time to discuss these results. Interested parties may participate in the call by dialing 877-461-2814 (in the United States) or 416-695-9753 (in Canada) approximately 10 minutes before the call is scheduled to begin and ask to be connected to the Stellar Pharmaceuticals Conference Call.

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc®, for the treatment of osteoarthritis; and Uracyst® and the Uracyst®Test Kit, its patented technology for the diagnosis and treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall. Stellar also has an in-licensing agreement for NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Stellar Pharmaceuticals Inc.
    Peter Riehl
    President & CEO
    (519) 434-1540 or Toll Free: 1-800-639-0643
    or
    Stellar Pharmaceuticals Inc.
    Arnold Tenney
    (416) 587-3200
    or
    INVESTOR RELATIONS COUNSEL:
    Seventh Circle Consulting, LLC
    Christine Petraglia
    (646) 354-8886